omniture

China Biopharmaceuticals Announces 2006 Year End Financial Results Conference Call

China Biopharmaceuticals Holdings, Inc.
2007-04-05 21:49 717

BEIJING, April 5 /Xinhua-PRNewswire/ -- China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP), a leading pharmaceutical company focused on the development, manufacturing and marketing of innovative drugs in China, today announced that Mr. Chris Peng Mao, Chairman and CEO of China Biopharmaceuticals, will host a conference call to discuss the Company's financial results for the fiscal year ended December 31, 2006.

The conference call will take place at 11:00 a.m. Eastern on Wednesday, April 11, 2007. Anyone interested in participating should call 1-800-322-9079 if calling within the United States, or 1-973-582-2717 if calling internationally, approximately 5 to 10 minutes prior to 11:00 a.m. Participants should ask for the China Biopharmaceuticals Year End Financial Results conference call. There will be a playback available until April 18, 2007. To listen to the playback, please call 1-877-519-4471 if calling within the United States or 1-973-341-3080 if calling internationally. Please use pass code 8655754 for replay.

This call is being webcast by ViaVid Broadcasting and can be accessed at http://www.cbioinc.com. The webcast may also be accessed at ViaVid's website at http://www.viavid.net. The webcast can be accessed through June 30, 2007 on either site. To access the webcast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player, please visit: http://microsoft.com/windows/windowsmedia/en/download/default.asp.

About China Biopharmaceuticals Holdings

China Biopharmaceuticals Holdings, Inc (Symbol: CHBP) is a vertically integrated pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases. CHBP's product portfolio includes 260 drugs already approved for manufacturing and marketing by the Chinese State Food and Drug Administration (SFDA). CHBP also has submitted 15 drug applications to the SFDA for its review during the calendar year of 2006. CHBP is a U.S.-listed public company with operating subsidiaries and senior management based in China. For further information, please visit our website at http://www.cbioinc.com .

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: China Biopharmaceuticals Holdings, Inc.
Keywords: Food/Beverages
collection